Oruka Therapeutics Inc. Common Stock vs Millicom International Cellular S.A. Common Stock — how do they compare? Oruka Therapeutics Inc. Common Stock trades at $75.2 (market cap $5.18B), while Millicom International Cellular S.A. Common Stock trades at $80.27 (market cap $13.34B). The key difference: Millicom International Cellular S.A. Common Stock is far larger — about 2.6× Oruka Therapeutics Inc. Common Stock's market cap, and Millicom International Cellular S.A. Common Stock pays a 3.77% dividend while Oruka Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Oruka Therapeutics Inc. Common Stock for 0 Days and Millicom International Cellular S.A. Common Stock for 0 Days on average.
| ORKA | TIGO | |
|---|---|---|
Market Cap | $5.18B | $13.34B |
Volume | 490,798 | 1,586,684 |
Sector | Health | Media |
52-Week High | $113.08 | $104.31 |
52-Week Low | $26.19 | $45.81 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $4.31B | $24.38B |
Dividend Yield | — | 3.77% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
TIGO trades at $79.54, down 0.92% on the day, with a neutral technical signal and key support at $79. The company reported strong 2025 results with $5.82B revenue and $1.32B net income, but 2026 earnings have missed expectations in two of the last three quarters. Recent news highlights its addition to Zacks' Strong Buy list and a consistent $0.75 quarterly dividend.
The stock offers a 12.9% upside to the consensus price target of $89.78, supported by solid profitability and cash flow, but faces risks from earnings volatility and high debt. Analyst sentiment is mixed with a Hold consensus, suggesting cautious optimism amid integration challenges from recent acquisitions.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Oruka Therapeutics, Inc. is a clinical-stage biotechnology company developing extended half-life monoclonal antibodies for plaque psoriasis, psoriatic arthritis, and related dermatologic conditions, with lead candidates ORKA-001 and ORKA-002 in clinical trials.
Read more on ORKA →Millicom International Cellular S.A. operates telecommunications and digital services under the Tigo brand across Latin America, providing mobile, fiber broadband, and pay-TV services. The company also offers mobile financial services through its Tigo Money business.
Read more on TIGO →